Proteolysis-targeting chimeras and their implications in breast cancer.

Abstract

Breast cancer (BC) is a highly heterogeneous neoplasm of the mammary tissue, causing the deaths of a large number of women worldwide. Nearly 70% and 20% of BC cases are estrogen receptor alpha positive (ERα+) and human epidermal growth factor receptor 2-positive (HER2+), respectively; therefore, ER and HER2 targeted therapies have been employed in BC treatment. However, resistance to these therapies has been reported, indicating a need for developing novel therapeutic strategies. Proteolysis-targeting chimeras (PROTACs) are new, promising therapeutic tools designed with a bimodular structure: one module allows specific binding to target proteins, and the other module allows efficient degradation of these target proteins. In this paper, PROTACs and their potential in controlling the progression of ERα and HER2+ BC are discussed.

• Authors: Angeles C Tecalco-Cruz, Jesús Zepeda-Cervantes, Josué O Ramírez-Jarquín, Alberto Rojas-Ochoa
• Journal: Exploration of targeted anti-tumor therapy (Explor Target Antitumor Ther) Vol. 2 Issue 6 Pg. 496-510 ( 2021) ISSN: 2692-3114 [Electronic] United States
• PMID: 36046115 (Publication Type: Journal Article, Review)
• Copyright: © The Author(s) 2021.